Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Age at diagnosis shapes stage and survival in diffuse large B-cell lymphoma: A 22-year, population-based study of 94,598 SEER patients

Aftab Ahmed, Rajesh Thirumaran, Manzer Ali et al. Nov 03, 2025 pp. 3666-3666 10.1182/blood-2025-3666

Abstract Background: Diffuse large B-cell lymphoma (DLBCL), the most common non-Hodgkin lymphoma, shows a sharp rise in...

Assessing the association between antiphospholipid syndrome and non-melanoma skin cancers: A case-control study on the role of a chronic inflammatory condition

Ruhi Kanwar, Ryan Chen, Daniel Nguyen et al. Nov 03, 2025 pp. 1334-1334 10.1182/blood-2025-1334

Abstract Antiphospholipid Syndrome (APLS) is an autoimmune hematological disorder defined by antiphospholipid antibodies and a hypercoagulab...

Early weight gain predicts nutritional recovery in children with sickle cell anemia and severe acute malnutrition in Nigeria

Safiya Gambo, Shehu Abdullahi, Hassan Murtala et al. Nov 03, 2025 pp. 4717-4717 10.1182/blood-2025-4717

Abstract Introduction Malnutrition in children with sickle cell anemia (SCA) is associated with higher rates of hospitalizations and early m...

Novel evidence shows that intracellular complement (complosome) expressed in hematopoietic stem cell progenitor cells regulates hematopoiesis at both the mitochondrial and cellular metabolism levels.

Magdalena Kucia, Justyna Jarczak, Michalina Kazek et al. Nov 03, 2025 pp. 3155-3155 10.1182/blood-2025-3155

Abstract Background. The intracellular complement network (complosome) has been identified to regulate lymphocyte-mediated immune responses...

Diluting high yield hematopoietic stem cell apheresis for autologous transplantation results in high viability of fresh grafts beyond 72h

Cristobal Frutos Ortiz, Carolina Acosta, Romi Alcaraz et al. Nov 03, 2025 pp. 7699-7699 10.1182/blood-2025-7699

Abstract Background: Autologous Hematopoietic Cell Transplantation (HCT) remains a highly efficient therapy primarily for patients with Mult...

The impact of clonal hematopoiesis on CAR-T cell therapy outcomes: A single-center analysis

Grace Mercadante, Joseph Van Amburg, Yash Pershad et al. Nov 03, 2025 pp. 4158-4158 10.1182/blood-2025-4158

Abstract Background: Clonal hematopoiesis (CH), including both clonal hematopoiesis of indeterminate potential (CHIP, VAF ≥2%) and micro-clo...

Pediatric inspired (BFM) protocol in adolescent and young adults (AYA) with acute lymphoblastic leukemia (ALL) in India: Real‑world treatment timelines and impact of delays on survival

Chepsy Philip, Hasmukh Jain, Prasanth Ganesan et al. Nov 03, 2025 pp. 8049-8049 10.1182/blood-2025-8049

Abstract Pediatric-inspired regimens have improved outcomes in adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL). T...

Machine learning uncovers prognostically distinct myeloma cast nephropathy phenotypes not captured by standard risk stratification systems

Michael Hughes, Yiran Peng, Shikun Wang et al. Nov 03, 2025 pp. 5756-5756 10.1182/blood-2025-5756

Abstract BACKGROUND Myeloma cast nephropathy (MCN), a driver of renal failure in 10-15% of newly diagnosed multiple myeloma (NDMM), remains...

Peripheral blood-based single-cell and genomic profiling of hematopoietic stem and progenitor cells enables accurate diagnosis and risk stratification in myeloproliferative neoplasms

Gal Dadi, Oren Milman, Nili Saar-Furer et al. Nov 03, 2025 pp. 5532-5532 10.1182/blood-2025-5532

Abstract Diagnosing myeloproliferative neoplasms (MPNs) remains challenging due to overlapping clinical and morphological features, and reli...

Selinexor-based non-intensive chemotherapy regimens adjusted according to early responses achieve high early remission in newly diagnosed AML or MDS

Shiyuan Zhang, Shuai Su, Bin Xu et al. Nov 03, 2025 pp. 1673-1673 10.1182/blood-2025-1673

Abstract Background Some newly diagnosed (ND) acute myeloid leukemia (AML) or higher-risk myelodysplastic syndrome (MDS) patients (pts) are...

Iron infusions in pregnant women are associated with comparable efficacy and safety compared to non-pregnant women

Steven Fein, Dayne Alonso, Gloria Campos et al. Nov 03, 2025 pp. 4477-4477 10.1182/blood-2025-4477

Abstract Background: Iron infusions in pregnant women who have iron deficiency anemia (IDA) have been shown to be effective, safe, and well-...

Cell intrinsic heme synthesis supports glycolysis for activation of naive CD4+ T cell

Kazuki Sakurai, Hiroki Kato, Yan Yan et al. Nov 03, 2025 pp. 627-627 10.1182/blood-2025-627

Abstract Revealing the mechanism by which naive CD4+ (nCD4+) T cells are activated is vital to understanding how acquired immunity is orches...

Real-world data on anti-BCMA CAR-T in Brazil: A single-center retrospective case series

Bianca Cal, Humberto Villefort, Vanessa Bovolenta et al. Nov 03, 2025 pp. 7523-7523 10.1182/blood-2025-7523

Abstract Background: The treatment landscape for relapsed/refractory Multiple Myeloma (R/R MM) in Brazil is unique, with both BCMA CAR-T (ci...

Impact of chimeric antigen receptor (CAR) product cell phenotypes on clinical outcomes following treatment with obecabtagene autoleucel (obe-cel)

Benjamin Simpson, Rehan Hussain, Mohammed Banani et al. Nov 03, 2025 pp. 33-33 10.1182/blood-2025-33

Abstract Background: The Phase Ib/II FELIX study (NCT04404660) evaluated obe-cel, a CD19-directed autologous CAR T-cell therapy with a fast...

Additional myelodysplasia-related genes mutations affected the clinical presentations and prognosis of patients with SRSF2/TET2 co-mutations

Michael Martin, Samuel Cockey, Veena Jajoo et al. Nov 03, 2025 pp. 2069-2069 10.1182/blood-2025-2069

Abstract Background Myeloid neoplasms (MN) display marked clinical and molecular heterogeneity. The 2022 WHO and ICC cla...

Outcomes associated with mitigating venous thromboembolism risk in pregnant patients with sickle cell disease

Sherraine Della-Moretta, Rina Welkie, Roberta Azbell et al. Nov 03, 2025 pp. 7970-7970 10.1182/blood-2025-7970

Abstract Introduction: Sickle cell disease (SCD) is an inherited hematologic disorder affecting around 100,000 Americans. Venous thromboembo...

Management of chronic myeloid leukaemia (CML) during pregnancy: A systematic review of maternal and foetal outcomes

Nicholas Pua, Harishini Thiruselvan, Alexandra Douglas et al. Nov 03, 2025 pp. 2845-2845 10.1182/blood-2025-2845

Abstract Introduction The introduction of tyrosine kinase inhibitors (TKIs) has transformed the treatment of Chronic Mye...

Disease status at initiation of blinatumomab and depth of response after cycle 1 are associated with survival in Philadelphia chromosome positive B cell acute lymphoblastic leukemia patients treated with blinatumomab and tyrosine kinase inhibitors

Ori Grossberger, Adi Sherban, Irina Amitai et al. Nov 03, 2025 pp. 3321-3321 10.1182/blood-2025-3321

Abstract Introduction: Philadelphia chromosome positive B cell acute lymphoblastic leukemia (Ph+ B-ALL) was historically...

Cardiopulmonary complications during pregnancy as a risk factor for cesarean delivery in a two center, sickle cell disease pregnancy cohort

Ria Arora, Amy Luo, Macy Gatti et al. Nov 03, 2025 pp. 2945-2945 10.1182/blood-2025-2945

Abstract Introduction: Pregnancy is high risk in sickle cell disease (SCD) with increased risk of pre-term and cesarean delivery. Little is...

Ropeginterferon alfa-2b in essential thrombocythemia of all risk levels ineligible for standard cytoreduction: 12-month primary endpoint analysis from the ROP-ET phase 3 study

Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, Jiri Mayer et al. Nov 03, 2025 pp. 485-485 10.1182/blood-2025-485

Abstract Introduction Essential thrombocythemia (ET) is a myeloproliferative neoplasm characterized by elevated platelet counts, risk of vas...

Apixaban or rivaroxaban for extended anticoagulation in patients with venous thromboembolism: A post hoc analysis of the renove clinical trial

Philippe Girard, Emilie Presles, Olivier Sanchez et al. Nov 03, 2025 pp. 740-740 10.1182/blood-2025-740

Abstract Background: Apixaban and rivaroxaban are approved for the initial and extended treatment of venous thromboembolism (VTE). Both drug...

Comparative effectiveness of CAR-T cell therapy vs. teclistamab in relapsed/refractory multiple myeloma: A real-world propensity-matched analysis revealing survival advantages and treatment disparities

Nehemias Guevara, Syeda Ashna Fatima Kamal, Noemy Coreas et al. Nov 03, 2025 pp. 2206-2206 10.1182/blood-2025-2206

Abstract Background: CAR-T cell therapy and bispecific antibodies (BsAbs) such as Teclistamab have expanded therapeutic...

Whole-genome analysis reveals shared early genetic alterations and subtype-specific immune evasion pathways in intravascular large B-cell lymphoma and immune-privileged large B-cell lymphoma

Takuto Mori, Kazuyuki Shimada, Kaito Mimura et al. Nov 03, 2025 pp. 7061-7061 10.1182/blood-2025-7061

Abstract Introduction Intravascular large B-cell lymphoma (IVLBCL) is a rare subtype of aggressive lymphoma characterized by selective growt...

Beliefs about medicines and self-reported medication adherence in patients with primary immune thrombocytopenia: A cross-sectional Study in Greece

Christina Lekarakou, Antonia Syrigou, Antonios Bertsias et al. Nov 03, 2025 pp. 4386-4386 10.1182/blood-2025-4386

Abstract Introduction Patient medication adherence is essential for the effectiveness of therapeutic interventions. Patients' perceptions of...

Overall survival and event-free survival in bone marrow versus peripheral blood as stem cell source for hematopoietic stem cell transplant in children and adolescents with hematological malignancies.

Gerardo Lopez Hernandez, Haydee Salazar, Rosa Maria Nidesha Ramírez Uribe et al. Nov 03, 2025 pp. 7745-7745 10.1182/blood-2025-7745

Abstract IntroductionRelapse risk after stem cell transplantation (SCT) is a key concern in treating childhood acute lymphoblastic leukemia...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page